Shire PLC (SHPG) Downgraded by Liberum Capital

Liberum Capital downgraded shares of Shire PLC (NASDAQ:SHPG) from a buy rating to a hold rating in a report issued on Thursday.

Other analysts have also recently issued research reports about the stock. Jefferies Group LLC set a $239.00 price objective on shares of Shire PLC and gave the company a buy rating in a research note on Saturday, March 18th. Cowen and Company reissued an outperform rating and issued a $325.00 price target on shares of Shire PLC in a research note on Wednesday, May 31st. Royal Bank of Canada set a $221.00 price target on shares of Shire PLC and gave the company a buy rating in a research note on Thursday, May 18th. Guggenheim reissued a neutral rating on shares of Shire PLC in a research note on Friday, February 17th. Finally, Goldman Sachs Group Inc reissued a conviction-buy rating on shares of Shire PLC in a research note on Friday, April 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. Shire PLC has a consensus rating of Buy and an average target price of $223.57.

Shire PLC (NASDAQ SHPG) opened at 175.85 on Thursday. Shire PLC has a 52-week low of $161.09 and a 52-week high of $209.22. The stock has a market cap of $52.38 billion, a price-to-earnings ratio of 180.36 and a beta of 1.53. The company has a 50-day moving average price of $179.03 and a 200 day moving average price of $174.76.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.22 by $0.41. Shire PLC had a net margin of 9.95% and a return on equity of 4.85%. The company had revenue of $3.57 billion during the quarter. During the same period in the prior year, the company posted $2.12 EPS. The firm’s revenue was up 109.0% on a year-over-year basis. On average, analysts expect that Shire PLC will post $15.00 earnings per share for the current year.

WARNING: “Shire PLC (SHPG) Downgraded by Liberum Capital” was originally published by sleekmoney and is the property of of sleekmoney. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://sleekmoney.com/shire-plc-shpg-downgraded-by-liberum-capital/1883981.html.

Institutional investors have recently modified their holdings of the company. Dumont & Blake Investment Advisors LLC raised its position in shares of Shire PLC by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 2,594 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 7 shares in the last quarter. Bienville Capital Management LLC raised its position in shares of Shire PLC by 0.4% in the fourth quarter. Bienville Capital Management LLC now owns 2,453 shares of the biopharmaceutical company’s stock valued at $418,000 after buying an additional 9 shares in the last quarter. Level Four Advisory Services LLC raised its position in shares of Shire PLC by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 2,745 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 13 shares in the last quarter. Covington Capital Management raised its position in shares of Shire PLC by 1.1% in the third quarter. Covington Capital Management now owns 1,241 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 14 shares in the last quarter. Finally, Thompson Davis & CO. Inc. raised its position in shares of Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 22.69% of the company’s stock.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/shire-plc-shpg-downgraded-by-liberum-capital/1883981.html

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *